Oxford, UK – 14 December 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announces the appointment of Ms Catherine Moukheibir to the Board as an Independent Non-Executive Director with effect from today.
Ms Moukheibir has extensive international experience in finance, capital markets and life sciences and is currently serving as a non-executive Board member with various companies, both listed (Biotalys, Ironwood Pharmaceuticals, Inc), and privately-owned (CMR Surgical Limited, Asceneuron SA. DNA Script and Noema Pharma).
Over the course of her career Ms Moukheibir, has served in senior executive roles and Board positions including at Kymab Limited, Innate Pharma S.A, Ablynx N.V, Genkyotex S.A, MedDay Pharmaceuticals, Zealand Pharma A/S, Zeltia S.A., and Creabilis. Prior to that, she was the CFO of Movetis N.V, overseeing the company’s IPO on Euronext and subsequent sale to Shire Pharmaceuticals. She started her career in investment banking and capital markets working in the US and London. She holds an MBA and a Masters in Economics from Yale University.
Dr. Roch Doliveux, Chairman of Oxford Biomedica, said: “I am delighted to welcome Catherine to the Board. Her international and impressive diverse experience as CEO, CFO and Board member of a broad range of healthcare companies and financial institutions will be very valuable as we continue to strengthen our position as a life-saving cell and gene therapy company.”
Ms Catherine Moukheibir said: “I am honoured to be joining the Board of Oxford Biomedica, a company that has contributed so much to society during the COVID-19 pandemic whilst also continuing to gain traction as a global leader in the gene and cell therapy space. I look forward to working with the Board and Group.”
Ms Catherine Moukheibir is currently a Non-Executive Director of Ironwood Pharmaceuticals, Inc. and Biotalys N.V. and in the last five years has been a Non-Executive Director of Ablynx N.V., Cerenis Therapeutics SA, GenKyoTex SA, Orphazyme A/S and Zealand Pharma A/S.
There are no other disclosures required to be made in accordance with LR 9.6.13R.
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: email@example.com
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations
Consilium Strategic Communications: T: +44 (0)20 3709 5700
Mary-Jane Elliott / Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics and Boehringer Ingelheim, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com